Daiichi Sankyo is a major Japanese pharmaceutical company with a focused strategy in oncology and cardiovascular medicine. The company has achieved global recognition for its antibody-drug conjugate pipeline, developed in partnership with AstraZeneca, which has demonstrated transformative results across multiple cancer types.

For international investors, Daiichi Sankyo represents one of the most closely watched names in Japanese pharma, driven by the commercial and pipeline potential of its ADC technology platform. The AstraZeneca collaboration provides substantial global commercialization reach and milestone payments, while the company's domestic cardiovascular franchise contributes a stable earnings base. Daiichi Sankyo's oncology pipeline positions it as a key participant in one of the most important areas of innovation in contemporary pharmaceutical research.